Idera Pharma (IDRA) Posts Break-Even Q3 EPS, Down 8c from Q308
More News related to IDRA
- Idera Pharma (IDRA) Posts Break-Even Q3 EPS, Down 8c from Q308
- Idera Pharma (IDRA) Presents IMO-2125 Preclinical Data
- Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
- Idera Pharma (IDRA) Announces TLR Patent Issuance
- Idera Pharmaceuticals Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use
More News related to Earnings
- Wells Fargo Initiates Coverage on Hologic (HOLX) with an Outperform
- Piper Jaffray Initiates Coverage on DragonWave (DRWI) with an Overweight
- Kaufman Bros. Initiates Coverage on Itron (ITRI) with a Hold
- FBR Capital Initiates Coverage on Stewart Information Services (STC)
- Citigroup Starts JDS Uniphase (JDSU) at Buy
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) reports Q3 EPS of $0.00, compared to $0.08 posted for the same period in 2008. Revenue for the quarter was $6.50 million, which compares to the estimate of $11.50 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
